Taken together, our results from our in vitro and ex vivo studies demonstrate the ability of toripalimab as an ICI to induce a strong T cell response dominated by an IFN-γ signature that could contribute to enhanced anti-tumor immune responses. This evidence concerns the gene IFNG and neoplasm.